Amendment: SEC Form SCHEDULE 13G/A filed by Allogene Therapeutics Inc.

Arie Belldegrun: 10100 Santa Monica Blvd., 15th Floor, Los Angeles, CA 90067 Bellco Legacy LLC: 10100 Santa Monica Blvd., 15th Floor, Los Angeles, CA 90067 Bellco Legacy IV LLC: 10100 Santa Monica Blvd., 15th Floor, Los Angeles, CA 90067 Vida Ventures LLC: 40 Broad Street, #201, Boston, MA 02109 Vida Ventures III, L.P.: 40 Broad Street, #201, Boston, MA 02109 Vida Ventures III-A, L.P.: 40 Broad Street, #201, Boston, MA 02109

Arie Belldegrun: United States and Israel Bellco Legacy LLC: Delaware Bellco Legacy IV LLC: Delaware Vida Ventures LLC: Nevada Vida Ventures III, L.P.: Nevada Vida Ventures III-A, L.P.: Nevada

Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of shares of Common Stock beneficially owned by such Reporting Person and is incorporated by reference. Row 9 of Dr. Belldegrun's cover page includes 3,180,554 shares of common stock issuable within 60 days of March 31, 2025 upon the exercise of stock options held by the Reporting Person and also includes (a) 4,710,120 shares of common stock beneficially owned by Bellco Legacy IV LLC, a limited liability company managed by Dr. Belldegrun and Rebecka Belldegrun, (b) 539,867 shares of common stock beneficially owned by Bellco Legacy LLC, a limited liability company owned and managed by trusts controlled by Dr. Belldegrun and Rebecka Belldegrun, (c) 1,798,163 shares of common stock beneficially owned by Vida Ventures LLC (Vida), a limited liability company of which VV Manager LLC is the manager, of which Dr. Belldegrun is a Senior Managing Director, (d) 1,720,172 shares of common stock beneficially owned by Vida Ventures III, L.P. (Vida III), a limited partnership of which Vida Ventures GP III, LLC (Vida GP III) is the manager, of which Dr. Belldegrun is a Senior Managing Director, and (e) 3,965 shares of common stock beneficially owned by Vida Ventures III-A, L.P. (Vida III-A), a limited partnership of which Vida GP III is the manager, of which Dr. Belldegrun is a Senior Managing Director. Dr. Belldegrun disclaims beneficial ownership of the shares held by Vida, Vida III and Vida III-A, except to the extent of any pecuniary interest therein, and other than for the purpose of determining his obligations under Section 13(d) of the Exchange Act.

Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of the shares of Common Stock beneficially owned by such Reporting Person and is incorporated by reference. This percentage is calculated based on 217,264,738 shares of common stock outstanding as of March 7, 2025, as reported in the Issuer's Quarterly Report on Form 10-K filed on March 13, 2025.

Row 5 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to vote or to direct the vote of Common Stock beneficially owned by such Reporting Person and is incorporated by reference.

Row 6 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to vote or to direct the vote of Common Stock beneficially owned by such Reporting Person and is incorporated by reference.

Row 7 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to dispose or to direct the disposition of Common Stock beneficially owned by such Reporting Person and is incorporated by reference.

Row 8 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to dispose or to direct the disposition of Common Stock beneficially owned by such Reporting Person and is incorporated by reference.